Table 1.

Univariate Cox PH analysis of PFS and OS for HRD and tBRCA

Overall cohortHGSOC subset
VariableLevelsHR (95% CI)PHR (95% CI)P
PFS
HRD status (≥42)HRD positive0.65 (0.46–0.93)0.0140.50 (0.34–0.73)0.00021
HRD negativeRefRef
HRD status (≥33)HRD positiveNDND0.51 (0.36–0.72)0.00014
HRD negativeNDRef
tBRCA mutation statusMutant0.61 (0.38–0.99)0.0340.48 (0.29–0.79)0.0017
Wild-typeRefRef
CCNE1 amplification statusaAmplified1.91 (1.32–2.75)0.00111.56 (1.04–2.34)0.038
Not amplifiedRefRef
OS
HRD status (≥42)HRD positive0.57 (0.36–0.92)0.0160.45 (0.27–0.74)0.0011
HRD negativeRefRef
HRD status (≥33)HRD positiveNDND0.43 (0.27–0.69)0.00033
HRD negativeNDRef
tBRCA mutation statusMutant0.64 (0.35–1.17)0.120.50 (0.26–0.95)0.022
Wild-typeRefRef
CCNE1 amplification statusaAmplified1.82 (1.15–2.88)0.0151.72 (1.04–2.85)0.043
Not amplifiedRefRef
  • aCCNE1 amplification status was determined for 248 of 250 patients in the full cohort, and 178 of 179 patients in the HGSOC subcohort.